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Abstract
Background: It has been controversial whether abciximab offered additional benefits for diabetic patients who underwent
percutaneous coronary intervention (PCI) with thienopyridines loading.
Methods: MEDLINE, EMBASE, the Cochrane library clinical trials registry, ISI Science Citation Index, ISI Web of Knowledge
and China National Knowledge Infrastructure (CNKI) were searched, supplemented with manual-screening for relevant
publications. Quantitative meta-analyses were performed to assess differences between abciximab groups and controls
with respect to post-PCI risk of major cardiac events (MACEs), angiographic restenosis and bleeding complications.
Results: 9 trials were identified, involving 2,607 diabetic patients receiving PCI for coronary artery diseases. Among those
patients who underwent elective PCI or primary PCI, pooling results showed that abciximab did not significantly reduce risks
of MACEs (for elective-PCI patients: RR1-month: 0.93, 95% CI: 0.60–1.44; RR1-year: 0.95, 95% CI: 0.81–1.11; for primary-PCI
patients: RR1-month: 1.05, 95% CI: 0.70–1.57; RR1-year: 0.98, 95% CI: 0.80–1.21), nor all-cause mortality, re-infarction and
angiographic restenosis in either group. The only beneficial effect by abciximab appeared to be a decrease 1-year TLR
(target lesion revascularization) risk in elective-PCI patients (RR1-year: 0.83, 95% CI: 0.70–0.99). Moreover, occurrence of
minor bleeding complications increased in elective-PCI patients treated with abciximab (RR: 2.94, 95% CI: 1.68–5.13,
P,0.001), whereas major bleedings rate was similar (RR: 0.83, 95% CI: 0.27–2.57).
Conclusions: Concomitant dosing of abciximab and thienopyridines provides no additional benefit among diabetic patients
who underwent PCI; this conclusion, though, needs further confirmation in larger studies.
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Introduction
Percutaneous coronary intervention (PCI) has been shown to
significantly reduce the prevalence of major cardiac events
(MACEs) in patients with myocardial infarction, while diabetic
patients represent a distinct sub-population at higher risk of
developing MACEs or restenosis after PCI than non-diabetic
population. Thus, it is plausible that diabetic patients might benefit
from a more aggressive anti-platelet aggregation therapy.
[1,2,3,4,5].
Anti-platelet therapy is an important adjunctive treatment that
reduces ischaemic complications in patients who underwent PCI
[6,7,8,9]. Two anti-platelet drugs, Thienopyridine (clopidogrel
or ticlopidine) and the platelet glycoprotein IIb/IIIa inhibitor
(abciximab) were conditionally recommended in coronary artery
disease (CAD) patients who underwent PCI in recently updated
guidelines [9,10,11].
Abciximab, a platelet glycoprotein IIb/IIIa inhibitor, acts by
competing with the ligand (e.g., fibrinogen) binding that is essential
for platelet bridging and aggregate formation [12,13,14,15,16,17].
Abciximab has been demonstrated in several studies [18,19,20] to
improve outcomes in diabetic patients treated with PCI; these
conclusion have been supported also by a meta-analysis in 2003
[20]. In recent years, however, thienopyridines loading has been
widely used before PCI to prevent MACEs and restenosis,
according to current practice guidelines as recommendation class
level I (‘‘Should be performed/administered’’) [9,11,21,22], and
thus, whether addition of abciximab is beneficial became elusive.
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22222. 2Thienopyridine (clopidogrel and ticlopidine) is a classic anti-
platelet agent, which is considered to be a significant advancement
for PCI [23,24,25]. Thienopyridine inhibits ADP-induced platelet
aggregation and signaling pathways within the platelet, which is
different from the anti-platelet mechanism elicited by GPIIb/IIIa
inhibitors such as abciximab [12,26,27,28], suggesting a possibility
for combination therapy, especially among the high-risk patients
who need stent implantation. Such combination a regimen was
also conditionally recommended in newly published guidelines
[29,30,31,32,33]. Some other investigators, however, have found
evidence to support the opposite view [34,35,36].
To address this issue, we carried out a systematic review and meta-




Data sources, search strategy, and selection criteria
Systematic literature searches were conducted in six databases:
Medline, the Cochrane Library, EMBASE, ISI Science Citation
Index, ISI Web of Knowledge, and China National Knowledge
Infrastructure (CNKI) in July, 2010. The search term ‘‘abciximab’’
was used in combination with ‘‘diabetes’’ and ‘‘PCI’’. The
‘‘references’’ sections of reviews and original articles were also
scanned for missing trials.
We included articles if they met all the following criteria: (1)
diabetic patients who underwent PCI were included, and types of
coronary artery diseases were stratified clearly; (2) Diabetes
mellitus was diagnosed according to the World Health Organiza-
tion criteria [37]; (3) a loading dose of thienopyridine (clopidogrel
or ticlopidine) should be adopted, and the same protocol of
abciximab-therapy were adopted in all trials (a bolus of 0.25 mg/
kg, a 12-h infusion (0.125 mg/kg/min)); (4) primary endpoints of
interest were the composite incidence of MACEs, the secondary
end point of interest was the frequency of angiographic restenosis,
which were described in Endpoints and definition; (5) a follow-up
duration $1-month; and (6) the study was designed as randomized
clinical trial.
Two reviewers (Wu YH, MD, PhD and Shi Y, PhD)
independently extracted study characteristics using standardized
forms. A total of 12 articles were identified, including 9 randomized
control trials (RCTs) such as DANTE, ISAR-SWEET, ISAR-
REACT, ISAR-REACT2, ASIAD, CADILLAC, BRAVE-3, and
two conducted by Deluca [34,35,36,38,39,40,41,42,43,44,45,46],
that were suitable for inclusion in the meta-analysis. Besides the
published data, the unpublished original data of diabetic patients
were extracted for analysis from ISAR-SWEET, ISAR-REACT,
ISAR-REACT2 and BRAVE3 data provided by Drs. Kastrati and
Mehilli (Deutsches Herzzentrum, Munich, Germany). All these
studies were high-quality RCTs (Dephi $6) [47]. The process of
selection was shown in Table S3 and Table S4.
For each trial, results at short-term (1-month) or long-term (6–
12 months) follow-up were extracted for this analysis, and the data
were retrieved according to the intention-to-treat principle.
Restrictions with respect to language or publication date were
not placed on these searches.
Endpoints and definitions
The primary endpoint of interest was the composite incidence
of MACEs at 1-month and 1-year. MACEs were a composite of
death of any cause, non-fatal re-infarction, and any repeated
intervention or revascularization of the target vessel as a result of
ischemia. During the follow-up period, re-infarction was defined as
new onset of ischemic symptoms or ischemic changes on
electrocardiography with over 2-fold normal total creatine kinase
value or new pathological Q-waves. Target lesion revasculariza-
tion (TLR) was defined as clinically driven percutaneous
revascularization or bypass of the target lesion or any segment
of the epicardial coronary artery containing the target lesion. The
frequency of angiographic restenosis (diameter stenosis .50%)
was the secondary endpoint of interest. Bleeding events were
defined as major or minor according to the thrombolysis in
myocardial infarction (TIMI) classification[48].
Data synthesis and Statistical analyses
Quantitative meta-analysis was carried out using Cochrane
Review Manager (Revman) software 5.0. Results were generated
using endpoint values for supplement minus control group, and
summarized as Forest plots. Relative risks (RRs) with 95%
confidence intervals (CIs) were used to assess the comparative
effect of abciximab versus control in diabetic patients treated by
PCI. A fixed-effect model with the Mantel–Haenszel method was
used to pool these RRs. The extent of heterogeneity across studies
was checked using the test and I
2 test (I
2 test quantifies the
proportion of total variation across studies due to heterogeneity
rather than chance). A P value #0.10 in combination with an
I
2.50% indicates significant heterogeneity, and the random-effect
model was used if heterogeneity was present.
The continuous data are expressed as mean value 6 SD. The
categorical data are presented as counts or proportions. The
differences between Abciximab and Placebo groups were assessed
by x
2 test in diabetic patients with 600 mg clopidogrel loading (data
from the three ISAR trials and BRAVE-3 trial). Sensitivity analyses
were carried out to assess the stability of the overall estimates with
regard to the use of PCI. A two-tailed P value that was less than 0.05
wasconsidered torepresent a significant variation alone.To assessfor
publication bias, funnel plots (i.e., plots of study results against
precision) were constructed. The Egger’s regression test was adopted
to test the asymmetry of funnel plots using STATA software (version
10.0, StataCorp, College Station, TX, USA). A P value ,0.10 was
considered significant [49,50].
We performed an ‘‘effect model analysis’’ [51] to investigate
whether the effect of abciximab was dependent on the baseline risk of
the studied population using SPSS software (SPSS Inc; Chicago,




After searching Medline, the Cochrane Library, EMBASE, ISI
Science Citation Index, ISI Web of Knowledge, and CNKI, we
identified 297 abstracts which were then reviewed for inclusion and
exclusion criteria (Figure 1 and Table S3). Review of abstracts and
titles resulted in exclusion of 281 reports, and the remaining 16
articles were extracted for further assessment. After full-text review, 4
of the remaining 16 articles were excluded because the information
from 2 papers was insufficient, 1 was a duplicate publication, and 1
was not the right subject for our review. The remaining 12 articles
(including 9 the separate trials listed inTable S1; 1-month and 1-year
outcomes of ISAR-REACT, ISAR-REACT2, and BRAVE3 trials
were published multiple articles) were included in our study, then we
contacted with authors and analyzed the original data of diabetic
patients. Original data of diabetic arms of ISAR-SWEET, ISAR-
REACT, ISAR-REACT2 and BRAVE-3 were provided by Drs.
Kastrati and Mehilli. We also checked our meta-analysis according to
the MOOSE guidelines, see Table S4.
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The characteristicsof the included studies (a total of 2607 diabetics)
were summarized in Table S1 and Table S2. All articles were
published between 2004 and 2010. Seven trials were performed in
Europe and US [34,39,40,42,43,44,45,46], [35,36], one in Asia [41],
and one in Brazil [38]. Among these studies, the diabetic patients in
the abciximab and placebo/inactive control arms were included in
our meta-analysis (n=2607). In three trials (5 articles were included),
only AMI patients who underwent primary PCI were included
[42,43,44,45,46], while non-AMI patients undergoing elective PCI
were investigated in the remaining trials. In four studies, diabetic
patients were restricted to Type2 diabetes mellitus [34,38,40,41],
while the remaining studies included diabetic patients diagnosed
according to the World Health Organization criteria [37]. The mean
follow-up duration was 8.6 months and ranged from 1 month to 12
months. Four of the 9 trials used a high loading dose of 600 mg
clopidogrel [34,39,40,43,44,45,46], and the remaining used 300 mg
clopidogrel or 500 mg Ticlopidine. All studies used the same dose of
abciximab (abolusof0.25 mg/kg, a 12-hinfusion(0.125 g/kg/min)).
Overall studies included were assessed according to the Dephi
criteria, and all of 9 trials were deemed high quality ($6) as shown in
Table S1. All trials were double-blind trials except DANTE trial [38].
3. Baseline patient characteristics
The 9 trials included a total of 2607 diabetic patients randomly
assigned to abciximab (1317) versus placebo/control (1290) groups.
Baseline characteristics of diabetics with elective and primary PCI
were listed separately in Table S2. The mean ages ranged from 59
to 66 and 68% of the patients were male. Patients who were
treated by insulin ranged from 1% to 43%. More than 50%
patients had hypertension and hyperlipidemia. Patients who had
previous myocardial infarction ranged from 10% to 67%, and
65% of the patients suffered from multivessel diseases. 95% of the
patients finally underwent stent implantation.
4. Efficacy and safety of abciximab in diabetic patients
undergoing elective PCI and primary PCI
4.1 Mortality (1-month and 1-year). Pooled results showed
that there was no significant difference in mortality between the
abciximab group and non-abciximab group in diabetics with
elective PCI at either 1-month (RR=1.21, 95% CI: 0.35–4.17,
P=0.77, see Figure 2A1) or 1-year follow-up (RR=1.13, 95%
CI: 0.69–1.83, P=0.63, see Figure 2B1). Similarly, abciximab did
not reduce 1-month (RR=1.40, 95% CI: 0.71–2.72, P=0.33,see
Figure 3A1) or 1-year mortality (RR=1.40, 95% CI: 0.87–2.25,
P=0.16, see Figure 3B1) in diabetics with primary PCI.
4.2 Re-infarction (1-month and 1-year). The 1-month
(Elective-PCI: RR=0.86, 95% CI: 0.53–1.40, P=0.55, Figure 2A2;
Primary-PCI: RR=0.92, 95% CI: 0.56–1.53, P=0.75, Figure 3A2)
and 1-year risk (Elective-PCI: RR=1.03, 95% CI: 0.66–1.61,
P=0.89, Figure 2B2; Primary-PCI: RR=1.01, 95% CI: 0.64–1.60,
P=0.96, Figure 3B2) for re-infarction showed no difference between
abciximab group and control group in either primary-PCI or elective-
PCI patients.
4.3 TLR (1-month and 1-year). For elective-PCI patients
with abciximab, there was a moderate reduction of risk in TLR at 1-
year follow-up (RR=0.83, 95% CI=0.70–0.99, P=0.04, see Figure
2B3) but not at 1-month follow-up (RR=0.77, 95% CI=0.35–1.73,
P=0.53, see Figure 2A3). This protective effect by abciximab,
however, did not appear to be significant at 1-month (RR: 1.30,
95%CI: 0.48–3.53, P=0.60, Figure 3A3) or 1-year follow-up (RR:
0.83, 95% CI: 0.51–1.33, P=0.43, Figure B3) in patients receiving
primary PCI.
4.4 MACEs (1-month and 1-year). Our results showed that
elective-PCI patients treated with abciximab did not display a
significant reduction in risk for MACEs as compared with those
received placebo at either 1-month (RR: 0.93, 95% CI: 0.60–1.44,
P=0.75, see Figure 2A4) or 1-year follow-up (RR: 0.95, 95% CI:
0.81–1.11, P=0.49, see Figure 2B4). Nor was any significant risk
reduction by abciximab observed in patients undergoing primary
PCI at either 1-month (RR: 1.05, 95% CI: 0.70–1.57, P=0.81, see
Figure 3A4) or 1-year follow-up (RR: 0.98, 95% CI: 0.80–1.21,
P=0.88, see Figure B4).
5. Angiographic restenosis (6-month)
Information on angiographic restenosis was available in 4 trials
[36,38,39,41] for patients undergoing elective PCI. No significant
difference in the rate of angiographic restenosis was observed
between the two groups (RR: 0.88, 95% CI: 0.74–1.05, P=0.15,
see Figure 4A).
Figure 1. Selection of studies included in systematic review.
doi:10.1371/journal.pone.0020759.g001
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6. Bleeding complications (in-hospital)
Abciximab significantly aggravated TIMI minor bleedings (RR:
2.62, 95% CI: 1.37–5.03, P=0.004; see Figure C) but not major
bleedings (RR: 0.83, 95% CI: 0.27–2.57, P=0.75; see Figure 4B)
in patients with elective PCI.
Two trials reported (ISAR-REACT2 and BRAVE3) bleeding
complications for ACS patients with primary PCI. The result of
ISAR-REACT2 showed that abciximab significantly increased the
risk of TIMI major bleeding in primary-PCI patients (RR=10.14,
P=0.006). A similar trend was also observed in BRAVES trial, but
was not statistically significant (RR=2.63, P=0.38). As to minor
bleeding complications, the result from ISAR-REACT2 suggested
that abciximab might aggravate TIMI minor bleeding (RR=4.12,
P=0.007), which was not consistent with the result of BRAVE3
(RR=0.88, P=0.89).
7. Publication bias and Assessment of within-group
heterogeneity
In order to evaluate the impact of potential publication bias, the
Begg’s funnel plot and Egger’s publication bias plot for the
treatment effect of abciximab at 1-month and 1-year were applied.
The results indicated that no publication bias is observed across
the studies, see Figure 5.
On the other hand, a moderate level of heterogeneity was
observed when evaluating the efficacy of abciximab on 1-year
mortality (I
2=44%, P=0.16), 1-year TLR (I
2=57%, P=0.43),
and angiographic restenosis (I
2=46%, P=0.15) in primary-PCI
patients. A slight level of heterogeneity was observed when
evaluating the efficacy of abciximab on 1-month re-infarction
(I
2=18%, P=0.55) and 1-month MACEs (I
2=11%, P=0.75) in
elective-PCI patients, and 1-year re-infarction (I
2=21%, P=0.96)
in primary-PCI patients. No heterogeneity was observed among
the remaining evaluations.
8. Sensitivity analyses
Sensitivity analyses were performed to further explore our
findings in elective and primary-PCI patients, and the results are
listed in Table 1. First, since ticlopidine is no longer used clinically,
we performed sensitivity analysis to ascertain its effect attributed to
the two studies, which used ticlopidine exclusively or partially
[38,42]. Second, the potential impact of loading time was assessed.
And finally, the potential impact of high (600 mg clopidogrel) and
low loading dose (300 mg clopidogrel or 500 mg ticlopidine) was
also evaluated. The results of sensitivity analyses were consistent
with our primary results.
9. Effect model analysis
To investigate whether the effect of abciximab in diabetic
patients with thienopyridines loading is related to the incidence of
MACEs in the study population, we performed an effect model
analysis by using Walter weighted regression model [51] (Figure 6).
It was found that the slopes of both sub-groups (including 1-month
MACEs, 1-year MACEs) deviate from 1 and included the origin,
indicating that the effect model was multiplicative. Overall results
supported that relative risk changes of MACEs was constant
regardless the incidence of events in the control group, and
Figure 2. Comparison of 1-month and 1-year outcomes between abciximab and control group in patients with elective PCI. Efficacy
of abciximab compared with control for (A1): 1-month mortality and (B1): 1-year mortality; (A2): 1-month reinfarction and (B2): 1-year reinfarction;
(A3): 1-month TLR and (B3): 1-year TLR; (A4): 1-month MACEs and (B4): 1-year MACEs in diabetic patients with elective PCI.
doi:10.1371/journal.pone.0020759.g002
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patients with thienopyridines loading might be the same in a
population with a higher MACEs.
Discussion
Although abciximab has been confirmed to improve outcomes
of CAD as class II recommendation in current guidelines for
elective and primary PCI [9,11,13,14,15,21,30,53,54], some
recent studies demonstrated that thienopyridines loading (level I
recommendation [9,11,21,29,30,55]) would mask the benefit of
glycoproteinIIb/IIIa inhibitor in these patients [34,40,56]. How-
ever, diabetes mellitus portents an excessive risk of thrombosis and
restenosis after PCI, and several studies have proved that abiximab
treatment could improve outcomes of diabetic patients undergoing
PCI without thienopyridines loading [18,20], suggesting that
diabetic patients might benefit from a potent anti-platelet
aggregation therapy induced by a combination of abciximab and
thienopyridines. Unfortunately, our meta-analysis results from 9
trials indicated that abciximab does not reduce the occurrence of
post-PCI MACEs, death, re-infarction, or angiographic restenosis
in diabetic patients with either elective PCI or primary PCI after
thienopyridines loading. It can even aggravate TIMI minor
bleeding in the patients studied. The ‘‘effect model analysis’’
showed that the negative effect of abciximab was independent of
the baseline risk of included population. It was worth of noting
that although previous studies suggested that ACS (acute coronary
syndromes) patients required a more intensive anti-platelet
treatment compared to those with stable coronary diseases, our
pooled results showed that abciximab did not provide additional
efficacy in such patients with either elective or primary PCI. Still,
the conclusion on primary-PCI patients should be interpreted
cautiously, as the number of trials included in this analysis was
limited.
It is possible that the conclusion could be affected by the
variables such as loading dose, loading time of thienopyridine, and
usage of ticlopidine. Though a 600 mg loading dose of clopidogrel
achieves a more rapid platelet inhibition in comparison to the
usual 300 mg dose clopidogrel or 500 mg ticlopidines [57,58], our
sensitivity analysis, stratified by applying-dose of thienopyridines,
showed that no adjuvant effect of abciximab could be observed
even in the low-loading group (Table 1). In another sensitivity
analysis, removal of studies that used ticlopidine also did not affect
the conclusion. Similarly, loading time did not appear to
significantly affect the efficacy of abiciximab when we excluded
the trial which did not use pretreatment.
The exact reasons for the negative results remained unknown,
although one potential explanation was that the loading dose of
thienopyridines could afford sufficient platelet inhibition, and
there was no incremental protection achieved by the additional
use of abciximab. However, this was challenged by the finding that
abciximab improved outcomes in non-DM patients with NSTEMI
even after thienopyridine loading (data not shown). Moreover, as
GPIIb/IIIa inhibitor exerts its anti-platelet effect in a mechanism
very different from clopidogrel, it appeared to be elusive why
combination of the two drugs induced no synergistic effect.
Another concern involves the potential safety problems caused
by combination therapy. Since both drugs could lead to post-
intervention bleeding, addition of GPIIb/IIIa inhibitor to
thienopyridine would possibly increase the incidence and the
Figure 3. Comparison of 1-month and 1-year outcomes between abciximab and control group in patients with primary PCI. Efficacy
of abciximab compared with control for (A1): 1-month mortality and (B1): 1-year mortality; (A2): 1-month reinfarction and (B2): 1-year reinfarction;
(A3): 1-month TLR and (B3): 1-year TLR; (A4): 1-month MACEs and (B4):1-year MACEs in diabetic patients with primary PCI.
doi:10.1371/journal.pone.0020759.g003
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statistically significant difference in the occurrence of major
bleedings between abciximab group and control group in average
patients [42,43,44,59]. In our analysis, abciximab did not increase
the rate of post-PCI major bleeding in diabetic patients with
elective-PCI, however, the results from ISAR-REACT2 and
BRAVE3 indicated that abciximab might increase the risk of
major bleeding in diabetics with primary-PCI. Moreover,
incidence of TIMI minor bleeding was also elevated significantly
with the use of abciximab. Nonetheless, considering the limited
sample size involved in the analysis of bleeding complications,
further trials are needed to clarify this issue, especially in the ACS
patients with primary-PCI. In addition, abciximab has been
reported to reduce estimated glomerular filtration rate(eGFR)in
CAD patients [60,61]. Thus, diabetic patients, who are prone to
renal lesion themselves due to the underlying disease, might be at
increased risk of renal insufficiency, which would aggravate the
outcomes [62,63].
Previous meta-analysis studies had evaluated the role of GPIIb/
IIIa inhibitor in diabetic patients undergoing PCI, however,
patients in most trials included in the two analyses did not receive
thienopyridine loading [18,20]. Furthermore, different kinds of
GPIIb/IIIa inhibitors such as tirofiban, eptifibatide, and abcix-
imab were used in these trials. Although these three GPIIb/IIIa
inhibitors all block the final common pathway of platelet
aggregation by occupying the GPIIb/IIIa receptor, abciximab,
Figure 4. Comparison of secondary endpoints between abciximab and control group in patients with elective PCI. Efficacy of
abciximab compared with control for (A) angiographic restenosis (B) TIMI major bleeding in diabetic patients with elective PCI; (C) TIMI minor
bleeding in diabetic patients with elective PCI.
doi:10.1371/journal.pone.0020759.g004
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and pharmacokinetics [19,64]. It is still not clear whether
abciximab has additional benefit compared to the other two
‘‘small molecule’’ agents (eptifibatide and tirofiban) [65,66,67,68],
and recent in vitro experiments have shown that eptifibatide
produced more potent and rapid effect on platelet disaggregation
than abciximab [69], suggesting heterogeneity in efficacy among
different types of GPIIb/IIIa inhibitors. Furthermore, there was
not enough evidence to confirm the efficacy of small molecular
agent (tirofiban/eptifibatide) in PCI patients with clopido-
grel loading (level of evidence is B in the latest guidelines
[9,11,21,22,30,55]). Thus, in comparison with prior meta-analysis,
our study included trials applying thienopyridine loading, and
abciximab was adopted with the same protocol in all included
trials, and as a result, added between-study homogeneity.
The current meta-analysis has several merits. First, this is the
first meta-analysis evaluating the benefits and safety of abciximab
in diabetic patients with thienopyridines loading. Our results
challenge the current guidelines on the usage of abciximab, which
was recommended in high-risk population including diabetic
patients even with thienopyridines loading. Second, we have used
different search methods and posed no restriction to language in
order to identify all eligible trials. Third, the included trials are of
high methodological quality. And fourth, we performed sensitivity
analysis to assess the validity and reliability of the primary results.
However, this meta-analysis also has its limitation in certain
aspects. First, the included trials vary in sample size and
intervention methods (both drug-eluting stents and bare metal
stents were included), although their influence was partially
alleviated by the absence of heterogeneity through x
2 test and
Figure 5. Publication bias analysis by funnel plots. Funnel plots for (A) 1-month MACEs for elective and primary PCI; (B) 1-year MACEs for
elective and primary PCI.
doi:10.1371/journal.pone.0020759.g005
Table 1. Sensitivity analyses for patients with elective and primary PCI.
Items No. of included patients RR (95%CI)
ELECTIVE PCI
Trials with only clopidogrel loading 1396 1-month MACEs: RR=0.93 (0.60–1.44)
1-year MACEs: RR=0.95 (0.81–1.11)
Trials with only pretreatment 1492 1-month MACEs: RR=0.98 (0.61–1.55)
1-year MACEs: RR=0.94 (0.79–1.11)
Trials with high loading dose 1142 1-month MACEs: RR=1.16 (0.70–1.93)
1-year MACEs: RR=0.94 (0.79–1.12)
Trials with low loading dose 604 1-month MACEs: RR=0.50 (0.21–1.20)
1-year MACEs: RR=0.98 (0.71–1.37)
PRIMARY PCI
Trials with only clopidogrel loading 720 1-month MACEs: RR=1.04 (0.67–1.62)
1-year MACEs: RR=0.93 (0.75–1.16)
Trials with only pretreatment 904 1-month MACEs: RR=1.05 (0.70–1.57)
1-year MACEs: RR=0.98 (0.80–1.21)
Trials with high loading dose 720 1-month MACEs: RR=1.04 (0.67–1.62)
1-year MACEs: RR=0.93 (0.75–1.16)
Trials with low loading dose 184 1-month MACEs: RR=1.10(0.40–3.03)
1-year MACEs: RR=1.44 (0.75–2.75)
doi:10.1371/journal.pone.0020759.t001
Abciximab in PCI Treatment for Diabetic Patients
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20759I-square test. Second, the majority of patients enrolled in these
trials have type 2 DM and the information on glycemic control of
patients during follow-up was not available in most trials. Third,
although our conclusion was based on the two types of AMI
including STEMI and NSTEMI (data no shown), the theory
should be assessed by more RCTs including either STEMI or
NSTEMI patients separately [59]. And fourth, we should be
cautious about the conclusion because of the limited sample size
and number of the trials included in the analysis. Additional,
multi-centered RCT is warranted to confirm this conclusion.
In conclusion, our meta-analysis suggests that abciximab does
not significantly decrease the prevalence of mortality, MACEs,
and angiographic restenosis at either short-term (1-month) or long-
term (1-year) follow-up. On the contrary, it increased TIMI minor
bleeding in diabetic patients who underwent either elective or
primary PCI after thienopyridines loading. The only potential
benefit was to decrease TLR rate in elective PCI at 1-year follow-
up. However, further clinical trials are needed to clarify this
important issue.
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